- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06281665
Behandlung mit Aspirin nach Präeklampsie: TAP-Studie (TAP)
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Alisse K Hauspurg, MD
- Telefonnummer: 412-641-1381
- E-Mail: janickia@upmc.edu
Studieren Sie die Kontaktsicherung
- Name: Sila Yavan, MS
- Telefonnummer: 4124174981
- E-Mail: yavans@upmc.edu
Studienorte
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- Rekrutierung
- University of Pittsburgh Magee-Womens Hospital
-
Kontakt:
- Sila Yavan, MS
- Telefonnummer: 4124174981
- E-Mail: yavans@upmc.edu
-
Hauptermittler:
- Alisse K Hauspurg, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Postpartum individuals ≥18 years old
- Preeclampsia diagnosis
Exclusion Criteria:
- Fetal anomaly
- Multiple gestation
- Pre-pregnancy hypertension
- Allergy or contraindication to low-dose aspirin
- Pre-pregnancy diabetes
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo Group
Similar appearing placebo pill daily for 6 months will be given to subjects. |
The control group will receive similar appearing placebo daily for 6 months. |
|
Experimental: Intervention Group
Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects |
The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percent of participants eligible, enrolled and retained (feasibility)
Zeitfenster: Baseline to approximately 6 months postpartum
|
To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia. |
Baseline to approximately 6 months postpartum
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Study visit systolic BP
Zeitfenster: 2 months postpartum
|
Mean study visit systolic BP |
2 months postpartum
|
|
Study visit diastolic BP
Zeitfenster: 2 months postpartum
|
Mean study visit diastolic BP |
2 months postpartum
|
|
Study visit systolic BP
Zeitfenster: 6 months postpartum
|
Mean study visit systolic BP |
6 months postpartum
|
|
Study visit diastolic BP
Zeitfenster: 6 months postpartum
|
Mean study visit diastolic BP |
6 months postpartum
|
|
Study visit mean arterial pressure
Zeitfenster: 2 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
2 months postpartum
|
|
Study visit mean arterial pressure
Zeitfenster: 6 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
6 months postpartum
|
|
Anti-hypertensive medication use
Zeitfenster: 2 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
2 months postpartum
|
|
Anti-hypertensive medication use
Zeitfenster: 6 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
6 months postpartum
|
|
Therapeutic intensity score
Zeitfenster: 2 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
2 months postpartum
|
|
Therapeutic intensity score
Zeitfenster: 6 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
6 months postpartum
|
|
Mean home systolic blood pressure
Zeitfenster: delivery through 6 months postpartum
|
Mean home systolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home diastolic blood pressure
Zeitfenster: delivery through 6 months postpartum
|
Mean home diastolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home mean arterial pressure
Zeitfenster: delivery through 6 months postpartum
|
Mean home mean arterial pressure |
delivery through 6 months postpartum
|
|
Mean daytime systolic blood pressure
Zeitfenster: 6 months postpartum
|
Mean daytime systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal systolic blood pressure
Zeitfenster: 6 months postpartum
|
Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime diastolic blood pressure
Zeitfenster: 6 months postpartum
|
Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal diastolic blood pressure
Zeitfenster: 6 months postpartum
|
Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal mean arterial pressure
Zeitfenster: 6 months postpartum
|
Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime mean arterial pressure
Zeitfenster: 6 months postpartum
|
Mean daytime mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall mean arterial pressure
Zeitfenster: 6 months postpartum
|
Mean overall mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall systolic blood pressure
Zeitfenster: 6 months postpartum
|
Mean overall systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall diastolic blood pressure
Zeitfenster: 6 months postpartum
|
Mean overall diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Classification of hypertension
Zeitfenster: 2 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
2 months postpartum
|
|
Classification of hypertension
Zeitfenster: 6 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
6 months postpartum
|
|
Endothelial function EC50%
Zeitfenster: 2 months postpartum
|
EC50% from microiontophoresis |
2 months postpartum
|
|
Endothelial function EC50%
Zeitfenster: 6 months postpartum
|
EC50% from microiontophoresis |
6 months postpartum
|
|
Endothelial function Emax
Zeitfenster: 2 months postpartum
|
Emax from microiontophoresis |
2 months postpartum
|
|
Endothelial function Emax
Zeitfenster: 6 months postpartum
|
Emax from microiontophoresis |
6 months postpartum
|
|
Endothelial function change in Emax
Zeitfenster: 2 to 6 months postpartum
|
Change in Emax between visits |
2 to 6 months postpartum
|
|
Endothelial function change in EC50%
Zeitfenster: 2 to 6 months postpartum
|
Change in EC50% between visits |
2 to 6 months postpartum
|
|
Change in systolic blood pressure
Zeitfenster: 2 to 6 months postpartum
|
Change in study visit mean systolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in diastolic blood pressure
Zeitfenster: 2 to 6 months postpartum
|
Change in study visit mean diastolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in mean arterial pressure
Zeitfenster: 2 to 6 months postpartum
|
Change in study visit mean arterial pressure between visits |
2 to 6 months postpartum
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Infektionen
- Eklampsie
- Präeklampsie
- Bluthochdruck, schwangerschaftsbedingt
- Hypertonie
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Schwangerschaftskomplikationen
- Toxämie
- Organische Chemikalien
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenwasserstoffe, aromatisch
- Phenole
- Benzolderivate
- Salicylate
- Hydroxybenzoates
- Aspirin
Andere Studien-ID-Nummern
- STUDY23080099
- K23HL168356 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.
IPD-Sharing-Zeitrahmen
Within a year after outcomes are published and no later than 3 years after the end of clinical activities.
IPD-Sharing-Zugriffskriterien
NHLBI data repository request process
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .